NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel during the next day after dosing with NBI-34060. The study will also examine the pattern and extent of nighttime awakenings as reported by the patients, as well as and the patient's sleep experience during treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
Sleep Disorders Center of Georgia
Atlanta, Georgia, United States
Clinilabs, Inc.
New York, New York, United States
Community Research
Cincinnati, Ohio, United States
Tri-State Sleep Disorders Center
Cincinnati, Ohio, United States
Assessments of Next-Day Function
Time frame: daily/six weeks
Quality of Life
Time frame: biweekly/six weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.